Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mcinnes, G. T
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

`Size is not everything`: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)

Gordon T Mcinnes

University of Glasgow, Division of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow, G11 6NT, UK, University of Glasgow, Division of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow, G11 6NT, UK

ALLHAT, the largest ever antihypertensiv e trial, compared cardiac outcomes in 42,418 high-risk individuals with mild-to-moderate hypertension, including 36% with diabetes, randomised to: 1) the thiazide-type diuretic, chlorthalidone; or 2) the ACE inhibitor, lisinopril; or 3) the calcium channel blocker, amlodipine. No differences between the groups were observed for the primary outcome coronary heart disease (CHD) but chlorthalidone was superior in preventing some cardiovascular disease events. Since diuretics are less expensive, it might be inferred that these drugs should be the preferred first-line antihypertensive therapy. However, the design and conduct of ALLHAT make interpretation of the results difficult. Despite its size, ALLHAT has few practical implications for management of hypertension.

Key Words: ACE inhibitor • amlodipine • calcium channel blocker • chlorthalidone • lisinopril • thiazide-type diuretic.

References

  • Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50:272-98.[Abstract/Free Full Text]
  • MacMahon S., Peto R., Cutler J. et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997;277:739-45.[Abstract/Free Full Text]
  • Hansson L., Lindholm LH, Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999;354:1751-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Lindholm LH, Niskanen L. et al. for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brown MJ, Palmer CR, Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356;366-77.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Hedner T., Lund-Johansen P. et al. for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and ß-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet 2000;356: 359-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pahor M., Psaty BM, Alderman MH et al. Health outcomes associated with calcium antagonists compared with the first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 352:1949-54.[CrossRef][Web of Science]
  • Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Zanchetti A., Carruthers SG et al. for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tuomilehto J., Rastenyte D., Birkenhager WH et al. for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.[Abstract/Free Full Text]
  • Cushman WC, Reda DJ, Perry HM et al. Regional and racial difference in response to antihypertensive medication use in a randomised controlled trial of men with hypertension in the United States. Arch Intern Med 2000;160:825-31.[Abstract/Free Full Text]
  • Rahman M., Douglas JG, Wright JT Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am 1997;26:125-44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Saunders E., Weir MR, Kong BW et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150: 1707-13.[Abstract/Free Full Text]
  • Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393-405.
  • Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-61.[Abstract/Free Full Text]
  • Deary AJ, Schumann AL, Murfet H., Haydock SF, Foo RS-Y, Brown MJ Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2000;20:771-7.[CrossRef]
  • Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-12.[Abstract/Free Full Text]
  • Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104.[Abstract/Free Full Text]
  • The IPPPSH Collaborative Group: Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985;3:379-92.[Web of Science][Medline] [Order article via Infotrieve]
  • Wikstrand J., Warnold I., Olsson G., Tuomilehto J., Elmfeldt D., Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988;259:1976-82.[Abstract/Free Full Text]
  • Wilhelmsen L., Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens 1987;5:561-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dahlöf B., Devereux RB, Kjeldsen SE et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cutler JA Calcium channel blockers for hypertension - uncertainty continues. N Engl J Med 1998;338:679-81.[Free Full Text]
  • Furberg CD, Psaty BM, Meyer JV Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92; 1326-31.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 4, 263-267 (2003)
DOI: 10.1177/14746514030030040501
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. R Petrie and M. Kirby
Too much of a good thing: 2004 guidance from NICE and BHS-IV on hypertension in diabetes
The British Journal of Diabetes & Vascular Disease, November 1, 2004; 4(6): 365 - 368.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mcinnes, G. T
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?